PMID- 7539865
OWN - NLM
STAT- MEDLINE
DCOM- 19950707
LR  - 20211203
IS  - 0022-5347 (Print)
IS  - 0022-5347 (Linking)
VI  - 154
IP  - 1
DP  - 1995 Jul
TI  - c-met proto-oncogene expression in benign and malignant human prostate tissues.
PG  - 293-8
AB  - Previously, we demonstrated that hepatocyte growth factor/scatter factor (HGF/SF) 
      is expressed by human bone stromal cells and is a powerful mitogen to prostatic 
      epithelial cells in culture. Based on these observations, we hypothesized that, 
      if prostate cancer cells in the prostate or bone environment respond to HGF/SF as 
      a mitogen, then they must express the HGF/SF receptor, which is coded by the 
      c-met proto-oncogene. We used immunohistochemical techniques to: 1) assess the 
      presence and localization of c-met protein in benign and malignant human prostate 
      tissues and 2) correlate the presence of c-met protein with tumor stage, grade 
      and androgen sensitivity. c-met protein immunostaining was consistently observed 
      in the basal epithelial layer of normal prostate glands but was absent in luminal 
      epithelial cells of the peripheral and transition zones. c-met protein 
      immunostaining was detected in 10 of 11 foci (91%) of high grade prostatic 
      intraepithelial neoplasia (PIN). Overall, c-met protein staining was noted in 36 
      of 43 (84%) primary prostate cancer samples versus 2 of 11 (18%) benign prostate 
      hyperplasia samples (p < 0.0001) and in 4 of 4 (100%) lymph node metastases, 23 
      of 23 (100%) bone marrow metastases and 1 of 3 (33%) other metastatic sites. 
      There was a clear relationship between c-met protein staining and higher grade 
      adenocarcinomas (p < 0.001). c-met protein is frequently detected in PIN and 
      higher grade prostate cancers; future studies should evaluate the biological 
      significance of these findings.
FAU - Pisters, L L
AU  - Pisters LL
AD  - Department of Urology, University of Texas M. D. Anderson Cancer Center, Houston 
      77030, USA.
FAU - Troncoso, P
AU  - Troncoso P
FAU - Zhau, H E
AU  - Zhau HE
FAU - Li, W
AU  - Li W
FAU - von Eschenbach, A C
AU  - von Eschenbach AC
FAU - Chung, L W
AU  - Chung LW
LA  - eng
GR  - R01-CA56307/CA/NCI NIH HHS/United States
GR  - R01-CA57361/CA/NCI NIH HHS/United States
GR  - R01-CA64863/CA/NCI NIH HHS/United States
GR  - etc.
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Urol
JT  - The Journal of urology
JID - 0376374
RN  - 0 (MAS1 protein, human)
RN  - 0 (Proto-Oncogene Mas)
RN  - 0 (Proto-Oncogene Proteins)
RN  - 67256-21-7 (Hepatocyte Growth Factor)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-met)
RN  - EC 2.7.10.1 (Receptor Protein-Tyrosine Kinases)
SB  - IM
MH  - Adenocarcinoma/genetics/metabolism/pathology
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Bone Marrow/metabolism
MH  - Bone Neoplasms/genetics/secondary
MH  - Epithelium/metabolism/pathology
MH  - *Gene Expression Regulation, Neoplastic
MH  - Hepatocyte Growth Factor/*genetics
MH  - Humans
MH  - Lymphatic Metastasis/genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prostate/metabolism/pathology
MH  - Prostatic Hyperplasia/genetics/metabolism/pathology
MH  - Prostatic Neoplasms/*genetics/metabolism/pathology
MH  - Proto-Oncogene Mas
MH  - Proto-Oncogene Proteins/*genetics
MH  - Proto-Oncogene Proteins c-met
MH  - Receptor Protein-Tyrosine Kinases/*genetics
EDAT- 1995/07/01 00:00
MHDA- 1995/07/01 00:01
CRDT- 1995/07/01 00:00
PHST- 1995/07/01 00:00 [pubmed]
PHST- 1995/07/01 00:01 [medline]
PHST- 1995/07/01 00:00 [entrez]
AID - S0022-5347(01)67297-5 [pii]
PST - ppublish
SO  - J Urol. 1995 Jul;154(1):293-8.